Understand the research.
Editorial revision November 5, 2026 · supplied November 6, 2026
Peptides and related compounds explained for general and scientific readers. Analogies explain a mechanism; they do not prove a treatment works.
Open the updated calculator →Start with the basic idea
Peptides are short chains of amino acids, the building blocks used to make proteins. Many act as biological messages. A receptor is a receiving point on or inside a cell; when the right message reaches it, the cell may change what it does. Some peptides work in other ways, such as binding a metal or interacting with membranes.
An analogy can make a mechanism easier to picture, but it is not proof that a treatment works. A compound may change a signal in a test tube without producing a useful or safe result in a person.
How to read the evidence
Established medical use. A specific medicine has evidence for a defined condition. This does not make every product with the same ingredient equivalent.
Human research. People have been studied, but the size, design, population and outcome determine what can be concluded.
Preclinical research. The evidence comes mainly from cells or animals and may not translate to people.
Unresolved identity. The product name is not enough to assign a reliable mechanism or clinical claim.
This is an educational explanation, not a dosing or treatment guide. Research labels, purity claims and biological plausibility do not establish safety for human use. Numbered sources at the end identify the studies or prescribing information used.
Directory and naming notes
The directory covers individual compounds, alternate names and blends. Separate names do not always identify distinct molecules. Naming distinctions below help readers connect each profile to the appropriate scientific literature.
Adamax • AOD-9604 • BPC-157 • Cagrilintide
CJC-1295 with DAC • CJC-1295 without DAC • CJC-1295 without DAC / Ipamorelin (CJC\IPA) • DSIP • Epithalon • GHK-Cu
GHRP-2 • GHRP-6 • GLOW • Glutathione • IGF-1 LR3
Ipamorelin • Kisspeptin • KLOW • KPV • LL-37
Melanotan 1 (MT-1) • Melanotan 2 (MT-2) • MOTS-C • NAD+
Oxytocin • PT-141 • Retatrutide (GLP 3, RT) • Selank
Semaglutide (GLP 1, R 1) • Semax • Sermorelin • SS-31 (MTP-131) • TB-500
Tesamorelin • Thymosin Alpha 1 (TA-1) • Tirzepatide (GLP 2, T 60) • Wolverine (BPC-157\TB-500) • HCG
Compound identity and naming
CJC-1295 with DAC and CJC-1295 without DAC have separate profiles because their molecular identity and duration of action differ. The without-DAC / Ipamorelin blend is described separately.
Kisspeptin-10 and kisspeptin-54 are different forms. Findings should be linked to the form actually studied.
Melanotan 2, Melanotan II and MT-2 refer to the same compound and are covered in one profile.
SS-31 and MTP-131 refer to elamipretide. Similar-looking catalog codes require confirmation before they are treated as synonyms.
The directory also covers related nonpeptide compounds, including NAD+. HCG is a larger glycoprotein hormone.
Adamax requires more precise identity documentation. RT RO-R3 has been consolidated under retatrutide according to the directory owner’s identification; catalog codes alone do not independently confirm a product’s molecular identity.
GLP 1, GLP 2, GLP 3, R 1, T 60 and RT are retained as directory labels supplied by the editor. They are not standardized molecular synonyms or receptor classifications. Semaglutide acts at GLP-1 receptors; tirzepatide acts at GIP and GLP-1 receptors; retatrutide acts at GIP, GLP-1 and glucagon receptors. The label GLP 2 here does not mean that tirzepatide is a GLP-2 receptor agonist.
Blend names do not define standardized formulations. Confirm every ingredient, molecular form and ratio when interpreting a product or study.
Editorial scope: This revision changes the explanations and presentation for a mixed public and scientific audience. It retains the guide’s selected primary studies and source review dated November 4, 2026; it is not a comprehensive new literature search or a live inventory of product availability.
Source review and interpretation
The underlying source review, dated November 4, 2026, included selected semaglutide and CJC-1295 pages at Doctor Pharmacist, sermorelin information at Empower, Adamax and BPC-157 pages at PeptideDosages, and relevant labeling at DailyMed. Primary studies remain the basis for the other profiles. Coverage varies by source.
DailyMed supplies submitted drug labeling. The applicable product label is used for mechanism, indication and warnings; presence in the database alone is not proof of FDA approval. Doctor Pharmacist and PeptideDosages are secondary educational resources. Empower provides pharmacy product information. Their claims are compared with original research rather than counted as independent clinical confirmation.
The review preserves three important distinctions: CJC with DAC and modified GRF 1–29 are not interchangeable; Adamax claims derived from Semax do not validate Adamax; and community BPC-157 schedules do not establish human efficacy. Online protocol tables were not imported into this descriptive guide.
Compound and blend explanations
Adamax
Adamax is described in research-product literature as a modified relative of Semax, a peptide investigated for effects on the nervous system. Interest centers on brain functions such as attention, memory and responses to stress. A useful way to picture the development idea is to imagine modifying a message so that it may be delivered or broken down differently. Whether those modifications actually improve delivery or function must be demonstrated for Adamax itself; its precise identity and effects remain insufficiently documented in the sources reviewed.
A compound-specific mechanism requires a verified sequence, terminal modifications and analytical characterization. Semax-related descriptions provide a development rationale, but are not evidence that Adamax has the same receptor interactions, neurotrophic effects, pharmacokinetics or tissue distribution.
No primary study establishing the identity and human effects of the exact Adamax product was verified in the source review supporting this guide. Claims about enhanced potency or brain penetration therefore remain unconfirmed.
PeptideDosages describes Adamax as a modified Semax-related compound and extrapolates some effects from Semax research. That description is a secondary-source claim, not independent confirmation of the product’s sequence, brain penetration, potency or human safety. Exact identity remains unresolved here. [45]
Full compound profile →AOD-9604
AOD-9604 is a laboratory-made peptide modeled on a small part of human growth hormone. Researchers study whether this fragment influences how the body breaks down and stores fat. Rather than supplying the entire hormone, the idea is to investigate one selected part of it. Think of removing a component from a large machine and testing what that component can do on its own; it may not reproduce the behavior of the complete machine.
Animal research suggests it can influence the breakdown and use of stored fat. It is only a fragment of the larger hormone, so it should not be assumed to reproduce all growth hormone effects.
Animal findings support a research hypothesis, not a proven human fat-loss treatment. Its name does not establish that it reliably burns fat in people. [2]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →BPC-157
BPC-157 is a laboratory-made peptide studied for its possible role in tissue repair and digestive-system biology. Researchers investigate how it affects the movement and survival of cells involved in repair, particularly in laboratory and animal injury models. One way to picture the proposed role is as a set of messages helping a repair crew reach a damaged area and coordinate its work. That picture explains the research interest without implying that human injuries are proven to heal faster.
In laboratory tendon cells and animal injury models, it has affected cell survival, movement and repair-related signaling. Scientists are studying several pathways rather than one fully established human mechanism.
The cited studies are preclinical. They do not establish that injections heal human tendon tears, injuries or digestive disorders. [3, 4]
Distinguish cell migration and animal repair findings from functional recovery in a controlled human trial. PeptideDosages itself identifies its vial chart as community-reported use rather than a clinically validated human schedule. The chart is therefore not used to establish efficacy or a recommended dose. [3, 4, 45]
Full compound profile →Cagrilintide
Cagrilintide is a long-acting peptide designed to imitate amylin, a hormone that helps the body recognize when it has had enough food. It is studied for appetite control and weight management. To understand the idea, imagine the body’s fullness signal as a conversation between the digestive system and the brain: cagrilintide is designed to make that message stronger and last longer.
It activates amylin-related receptors involved in appetite control, helping strengthen signals that a meal has been sufficient. It works through a different receptor system from GLP-1 medicines.
A randomized human trial found weight loss. Trial results apply to the tested formulation and study conditions, not automatically to research-vial products. [5]
Compare randomized groups, treatment duration, discontinuations and adverse events alongside weight and metabolic outcomes. Results depend on the tested population and formulation. A trial of a combination cannot isolate the contribution of one ingredient without suitable comparison groups.
Full compound profile →CJC-1295 with DAC
CJC-1295 with DAC is a peptide designed to imitate the natural signal that tells the pituitary gland to release growth hormone. DAC is a chemical feature that allows it to attach to a carrier protein in the blood, helping it remain in circulation longer. The body normally releases growth hormone in pulses. DAC makes the stimulating compound remain available longer; it does not necessarily turn those pulses into a continuous stream. Think of keeping a request available at a factory while the factory still releases its output in batches.
The compound acts through the growth-hormone-releasing hormone pathway. Its drug affinity complex (DAC) promotes binding to circulating albumin, prolonging exposure. This distinguishes long-acting CJC-1295 from modified GRF 1–29, commonly sold under the name CJC-1295 without DAC.
Human research on long-acting CJC-1295 showed increases in growth hormone and IGF-1. That does not prove anti-aging benefits or validate no-DAC products by association. [6]
In two short randomized studies in healthy adults, the long-acting compound had an estimated half-life of 5.8–8.1 days, with sustained GH and IGF-1 responses. These are pharmacodynamic outcomes, not proof of improved recovery or longevity. They cannot be assigned to modified GRF 1–29. [6]
For research design, the DAC form permits investigation of prolonged GHRH-receptor stimulation and sustained hormone exposure. A human study found increased mean and trough GH concentrations with preserved pulsatile secretion after long-acting CJC-1295. Duration of drug exposure and the pattern of hormone secretion are therefore separate variables. [48]
Full compound profile →CJC-1295 without DAC
CJC-1295 without DAC is a common product name for modified GRF 1–29, a peptide related to the body’s natural growth-hormone-releasing signal. It prompts the pituitary gland to release growth hormone without the albumin-binding feature used in the DAC form. The body normally releases growth hormone in bursts rather than at a steady rate. The shorter-lived stimulus from the without-DAC form is relevant to research on brief stimulation of that system. Think of a short request to a hormone factory rather than a request kept available for days. This makes the difference in signal duration easier to picture, but does not establish that the resulting hormone pattern more closely matches normal physiology.
Modified GRF 1–29 is a growth-hormone-releasing hormone analogue. It acts through the GHRH receptor pathway and lacks the drug affinity complex responsible for albumin binding in long-acting CJC-1295. Commercial naming can obscure this distinction, so molecular sequence and formulation should be specified when identifying a study material.
The human CJC-1295 studies cited in this guide evaluated the long-acting compound. Their reported half-life and sustained GH and IGF-1 responses should not be assigned to the without-DAC form. Those results also do not establish clinical benefits for a modified GRF 1–29 product. [6]
Research interpretation should distinguish receptor activity and changes in circulating hormones from outcomes such as physical function or recovery. Evidence for a combination containing ipamorelin must be evaluated separately from evidence for either individual ingredient.
For research design, modified GRF 1–29 allows investigation of a shorter-lived GHRH-receptor stimulus than the albumin-binding DAC compound. Reproducing physiological GH secretion would require assessment of pulse timing, amplitude, frequency and baseline concentrations, rather than inference from drug half-life alone. Direct comparative evidence establishing a more physiological pattern is not provided by the studies cited here; long-acting CJC-1295 has also preserved GH pulsatility in humans. [6, 48]
Full compound profile →CJC-1295 without DAC / Ipamorelin (CJC\IPA)
CJC-1295 without DAC / Ipamorelin combines a shorter-acting growth-hormone-releasing hormone analogue with ipamorelin. Both ingredients are intended to encourage the body’s own growth hormone release through different signaling pathways. The without-DAC ingredient supplies a shorter-lived request for growth hormone release, while ipamorelin adds a signal through a different receptor pathway. This combination is relevant to research on brief stimulation of the body’s own hormone-release system. Picture two communication lines sending requests to the same factory. Their combined effect cannot be assumed to reproduce the timing or size of the body’s natural growth hormone bursts.
The CJC component targets the growth-hormone-releasing hormone pathway; ipamorelin targets the ghrelin receptor pathway. The combination is intended to stimulate growth hormone release through two different inputs.
This explains the rationale, not a demonstrated benefit of the finished blend. Evidence on individual ingredients does not establish the combination’s long-term safety or effectiveness. [6, 7]
Record every component, sequence, ratio and formulation. A study of one ingredient does not establish efficacy, stability or interaction effects of the combination. A useful comparison would test the complete blend against its components and an appropriate control.
The duration of the CJC component does not establish the complete blend’s pharmacokinetic or GH-secretion profile. Studies would need to measure exposure to both ingredients and use serial GH sampling to characterize pulse frequency, amplitude and baseline secretion. Demonstrating that a compound stimulates endogenous GH is not equivalent to demonstrating a physiological secretion pattern or superiority to the DAC form. [6, 7, 46, 48]
Full compound profile →DSIP
DSIP, short for delta sleep-inducing peptide, is a small peptide investigated for its relationship to sleep and stress-related processes. Its name reflects the research that led to its discovery, rather than a dependable promise that it will induce sleep. A helpful analogy is a possible adjustment to a sleep control panel with many interacting settings. Researchers still need to establish which settings it affects and whether those changes produce meaningful improvements in people.
Its proposed role involves sleep-regulating brain systems, but a dependable receptor-level explanation and consistent human sleep effect have not been established.
Small human trials have produced mixed results. One placebo-controlled study concluded that short-term treatment was unlikely to provide major therapeutic benefit. [8]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Epithalon
Epithalon is a short synthetic peptide studied in cellular aging research. Some experiments examine its relationship to telomeres, the protective ends of chromosomes. To picture telomeres, think of the tips that keep shoelaces from fraying. Researchers are asking whether Epithalon influences the cell’s maintenance of those tips; changes in cultured cells do not by themselves show that a person will live longer or age more slowly.
Cell experiments have reported effects on telomerase, an enzyme that helps maintain telomeres—the protective ends of chromosomes. Changing this process in a dish is not the same as reversing aging in a person.
The cited evidence concerns cultured cells. It does not establish longer human life, rejuvenation or a safe anti-aging treatment. [9]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →GHK-Cu
GHK-Cu is a small peptide attached to copper, studied for its role in skin biology and tissue remodeling. Researchers examine how it affects collagen and other materials that provide structure around cells. Imagine a tissue as a building with a supporting framework: GHK-Cu is investigated for messages that may influence the maintenance crew working on that framework. Its effects depend on the tissue, formulation and way it is delivered.
In cell experiments, it influences collagen production and other parts of the supporting material around cells. Copper binding is part of its chemistry, but it is not simply a copper supplement.
Laboratory findings help explain interest in skin applications. They do not establish whole-body benefits from injections; formulation and route matter. [10]
Separate normal biological function from the effects of administering extra compound. Record the route, formulation, tissue studied and clinical endpoint. Findings from oral, topical, nasal or injected exposure should not be transferred between routes without supporting evidence.
Full compound profile →GHRP-2
GHRP-2 is a synthetic peptide that stimulates a signaling system involved in growth hormone release and hunger. It imitates some of the actions of ghrelin, a natural hormone that helps connect feeding with hormone regulation. Picture a control button wired to more than one system: activating it can affect both hormone release and appetite. Those measurable changes are the starting point for research into its broader effects.
It activates the growth hormone secretagogue receptor, which can increase growth hormone release and appetite. Human experiments have measured both hormone and food-intake changes.
Demonstrating a hormone increase does not demonstrate improved recovery, muscle performance or healthy aging. [11]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Full compound profile →GHRP-6
GHRP-6 is a synthetic peptide studied for its ability to prompt growth hormone release through the body’s ghrelin signaling system. This system also participates in hunger and energy regulation. A simple analogy is a key that opens a communication channel to the pituitary gland. The response depends on the body’s other hormonal signals, so activating that channel does not guarantee a particular change in muscle, recovery or body composition.
It stimulates growth hormone release, interacting with the body’s own growth-hormone-releasing hormone signals. Its biological activity overlaps with hunger-related pathways.
Human studies have examined hormone responses and how the body processes it. Those findings do not establish routine athletic or anti-aging benefits. [7, 12]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Full compound profile →GLOW
GLOW is a blend name used for combinations of GHK-Cu, BPC-157 and TB-500. These ingredients are individually associated with research into skin structure, cell movement and tissue repair. Think of the blend as a collection of tools selected for related jobs. Combining tools provides a research rationale, but it takes testing of the complete blend to show whether they work well together. Ingredient identity and proportions need to be specified for each formulation.
The concept combines ingredients studied in tissue signaling, collagen biology and repair-related processes. The proposed actions come from the individual ingredients; a combined clinical effect has not been established here.
No controlled human study of this exact blend was verified. The TB-500 identity distinction described later also applies to blends containing it. [3, 10, 13]
Record every component, sequence, ratio and formulation. A study of one ingredient does not establish efficacy, stability or interaction effects of the combination. A useful comparison would test the complete blend against its components and an appropriate control.
Full compound profile →Glutathione
Glutathione is a naturally occurring molecule made from three amino acids that helps cells manage reactive chemicals produced during normal activity. It is part of the body’s antioxidant defenses. Picture a reusable cleanup system: glutathione participates in reactions that limit chemical damage, then can be recycled for further use. Its normal importance to cells is well established, while the effects of taking additional glutathione depend on how it is given and what outcome is measured.
It helps neutralize reactive chemicals and supports enzymes that process certain unwanted compounds. The body continually uses and recycles it as part of normal cellular protection.
An oral supplementation trial found increased glutathione stores. That result does not prove broad “detox,” disease-treatment or anti-aging benefits, and it does not validate injectable use. [14]
Separate normal biological function from the effects of administering extra compound. Record the route, formulation, tissue studied and clinical endpoint. Findings from oral, topical, nasal or injected exposure should not be transferred between routes without supporting evidence.
Full compound profile →IGF-1 LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, a natural protein signal involved in growth and the use of nutrients by tissues. The modification changes how strongly it attaches to proteins that normally bind and regulate IGF-1. Imagine a message that is usually carried and held by escorts: changing its attachment to those escorts can change how readily it reaches cells. This makes it useful to study growth signaling, but does not establish safe muscle-building use in people.
It can activate IGF-1 receptors and is modified to bind less strongly to certain IGF-binding proteins. This changes its availability and activity; it should not simply be described as a harmless or predictably longer-lasting form of IGF-1.
The cited work is experimental, including animal research. It does not establish safe muscle-building use in people or equivalence to a prescribed IGF-1 medicine. [15]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Full compound profile →Ipamorelin
Ipamorelin is a synthetic peptide studied for its ability to encourage the pituitary gland to release growth hormone. It works through a receptor also used by the hunger-related hormone ghrelin. To picture the distinction, think of sending an order to the body’s hormone factory rather than delivering growth hormone directly. Whether the resulting hormone response produces a meaningful health benefit is a separate research question.
It stimulates the ghrelin receptor pathway rather than supplying growth hormone directly. Early experiments found a relatively selective hormone-release pattern, but selectivity does not mean absence of risk.
The cited discovery experiments support its mechanism. They do not establish long-term benefits for sleep, body composition or athletic recovery in otherwise healthy people. [7]
A human intravenous infusion study measured an approximately 2-hour terminal half-life and a discrete GH response. Route and study design matter: these data do not establish the duration or clinical effects of a subcutaneous commercial blend. The original selectivity experiments were largely in animals. [7, 46]
Full compound profile →Kisspeptin
Kisspeptin refers to a family of natural peptides that help start the body’s reproductive hormone signals. These messages travel from the brain through the pituitary gland to the testes or ovaries. Think of a relay race: kisspeptin helps initiate the handoff, and several other hormones carry the message onward. Different forms, including kisspeptin-10 and kisspeptin-54, have been studied and can behave differently.
It stimulates brain signals that release GnRH, which prompts the pituitary to release LH and FSH. Those hormones help regulate the testes and ovaries.
Human studies show hormone effects, but responses depend on the form, exposure and population. Results for kisspeptin-54 cannot simply be transferred to kisspeptin-10. [16, 17]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Full compound profile →KLOW
KLOW is a blend name used for GHK-Cu, BPC-157, TB-500 and KPV. It brings together ingredients studied in tissue remodeling, repair and inflammation-related biology. A useful analogy is a toolkit containing tools for several connected tasks. The extra ingredient broadens the proposed research rationale, but does not establish that the mixture works better than its components. Exact ingredients and proportions are essential to interpreting a particular formulation.
It combines proposed tissue-repair signals with KPV’s experimentally observed effects on inflammation signaling. This is a description of the ingredients’ research rationale, not a verified result of mixing them.
No controlled human study establishing the benefits of this exact blend was verified. More ingredients also make it harder to identify which one caused an effect. [10, 18]
Record every component, sequence, ratio and formulation. A study of one ingredient does not establish efficacy, stability or interaction effects of the combination. A useful comparison would test the complete blend against its components and an appropriate control.
Full compound profile →KPV
KPV is a very short peptide studied for its influence on inflammation-related signals. It corresponds to part of a larger natural hormone, alpha-melanocyte-stimulating hormone. One way to understand the research is to picture inflammation as an alarm system: useful when responding to harm, but potentially damaging when activity is excessive or prolonged. Laboratory studies investigate whether KPV can quiet some of those signals without assuming that it treats every inflammatory condition.
Cell and mouse studies found reduced activity in inflammation-related pathways, including NF-kappaB. In the intestine, a peptide transporter called PepT1 helped bring it into cells.
The cited study used cells and mouse colitis models. It does not establish an effective treatment for human IBS, inflammatory bowel disease or general inflammation. [18]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →LL-37
LL-37 is a naturally occurring peptide involved in the body’s early defenses against microbes. It also helps shape immune signaling and tissue responses to injury. Think of it as both a security guard and a messenger: it can interact with microbes while influencing how nearby cells respond. These overlapping roles make its effects dependent on location and circumstances, rather than those of a simple all-purpose antibiotic.
It can interact with microbial membranes and also influence immune-cell behavior and wound responses. Its effects vary with the tissue and circumstances; it is not simply a universal antibiotic.
Topical wound trials exist, with mixed overall findings. Their results do not establish that systemic injections treat chronic infections or broadly improve immunity. [19, 20]
Separate normal biological function from the effects of administering extra compound. Record the route, formulation, tissue studied and clinical endpoint. Findings from oral, topical, nasal or injected exposure should not be transferred between routes without supporting evidence.
Full compound profile →Melanotan 1 (MT-1)
Melanotan 1, also called Melanotan I or afamelanotide, is a synthetic peptide that imitates a natural signal involved in skin pigmentation. It encourages pigment-producing cells to make more eumelanin, the brown-black pigment in skin. Think of it as a message to the skin’s pigment workshop asking it to increase production. A prescription implant containing afamelanotide has a specific medical use in a rare light-sensitivity disorder; this is different from assuming that every product sold as MT-1 is equivalent.
Afamelanotide is a 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH), also known as [Nle4,D-Phe7]-α-MSH. It activates melanocortin 1 receptors (MC1-R), increasing eumelanin production independently of sunlight or artificial UV exposure. MT-1 and MT-2 are distinct molecules, so their pharmacology and clinical evidence should be evaluated separately. [49, 50]
The FDA-approved afamelanotide implant, Scenesse, is indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). This indication concerns a defined disorder and formulation, rather than general cosmetic tanning or prevention of skin cancer. Evidence for the implant does not establish the identity, delivery characteristics or safety of research-vial products labeled MT-1. [49]
Research interpretation should distinguish increased pigmentation from clinically measured light tolerance. Relevant variables include formulation, exposure, underlying disease and adverse effects. The prescribing information describes pigmentary changes, including darkening of existing moles and freckles, and recommends twice-yearly full-body skin examinations; patients should maintain sun and light protection measures. [49]
Full compound profile →Melanotan 2 (MT-2)
Melanotan 2 (also written Melanotan II) is a synthetic peptide that activates signals involved in skin pigmentation. It is also known as MT-2 or MT-II. Researchers have examined its effects on tanning and other functions because the same receptor family is used in several parts of the body. Imagine a control panel connected to multiple rooms: changing one setting may influence more than skin color. Increased pigment does not establish protection from sun damage.
It activates melanocortin receptors, including receptors involved in making skin pigment. Its actions are not limited to skin, which helps explain effects on other systems.
A small early human study found tanning effects and adverse symptoms. Increased pigmentation does not establish protection against sun damage or skin cancer. [21]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →MOTS-C
MOTS-c is a short peptide associated with mitochondria, the structures that help cells convert fuel into usable energy. Researchers study how it participates in the response to changes in fuel supply and metabolic stress. Imagine a power plant sending a message to the rest of a city to adjust energy use. This analogy describes the signaling idea, while much of the evidence for administering MOTS-c still comes from cells and animals.
Experimental work links MOTS-c to energy-sensing pathways such as AMPK and to changes in how cells respond to metabolic stress.
Much of the treatment evidence comes from cells and animals. Human observations about natural MOTS-c do not prove benefits from injecting it. [23, 24]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →NAD+
NAD+, short for nicotinamide adenine dinucleotide, is a molecule that cells use in energy production and other essential chemical reactions. It helps transfer electrons and is consumed by some enzymes involved in cellular maintenance. A useful picture is a reusable shuttle carrying small loads between steps in an energy system. The body’s need for NAD+ does not automatically mean that giving extra NAD+ improves energy, health or longevity.
It helps transfer electrons during energy production and is used by enzymes involved in processes such as DNA repair. Its normal biological importance does not establish that extra NAD+ produces extra benefit.
A small infusion study tracked NAD+ metabolism; it did not establish rejuvenation. Studies of NAD+ precursors also cannot automatically validate direct NAD+ injections. [25]
Separate normal biological function from the effects of administering extra compound. Record the route, formulation, tissue studied and clinical endpoint. Findings from oral, topical, nasal or injected exposure should not be transferred between routes without supporting evidence.
Full compound profile →Oxytocin
Oxytocin is a natural peptide hormone best known for helping the uterus contract during childbirth and helping release milk during breastfeeding. It also participates in brain signaling, where its effects are more complex. Imagine the same message arriving at different departments: each department responds according to its own equipment and responsibilities. This helps explain why its established medical uses do not translate directly into predictable effects on bonding or mood.
It binds oxytocin receptors, triggering responses that depend on the tissue. Its effects on labor are well established; its role in social behavior is more complex than the nickname “love hormone” suggests.
Prescription oxytocin has established obstetric uses. Those uses do not validate self-directed injections for bonding, mood or sexual enhancement. [26]
Separate normal biological function from the effects of administering extra compound. Record the route, formulation, tissue studied and clinical endpoint. Findings from oral, topical, nasal or injected exposure should not be transferred between routes without supporting evidence.
Full compound profile →PT-141
PT-141, also called bremelanotide, is a synthetic peptide that acts on a receptor family involved in several nervous-system functions. Its prescription use concerns a specific form of low sexual desire. A helpful analogy is a signal entering the brain’s desire-related communication network, rather than a valve that simply increases blood flow. Its effects and approved use depend on the clinical setting and patient population.
Its sexual-desire effects are thought to involve central nervous system pathways, although the exact mechanism responsible for benefit is not fully known.
The prescription product Vyleesi has a specific indication for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That approval does not apply broadly to all users or research-vial products. [27]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Retatrutide (GLP 3, RT)
Retatrutide is a peptide studied for obesity and metabolic disease that acts on three hormone receptor systems: GLP-1, GIP and glucagon. These systems participate in appetite, blood sugar regulation and the use of energy. Picture one controller designed to coordinate three related control panels. Researchers investigate whether this combined activity produces meaningful benefits and what risks accompany those effects.
These pathways influence appetite, blood sugar regulation and energy metabolism. Combining them in one molecule is intended to change several parts of metabolic control together.
Randomized human trials report substantial weight loss. Those findings concern a defined clinical-trial drug and do not establish the identity, quality or safety of separately sold research products. [28]
Compare randomized groups, treatment duration, discontinuations and adverse events alongside weight and metabolic outcomes. Results depend on the tested population and formulation. A trial of a combination cannot isolate the contribution of one ingredient without suitable comparison groups.
Full compound profile →Selank
Selank is a synthetic peptide investigated for effects on anxiety-related processes and nervous-system signaling. Researchers examine whether it influences chemical communication associated with the brain’s response to stress. Imagine adjusting the sensitivity of a communication network rather than switching emotions on or off. The proposed effects remain dependent on the experimental setting, and laboratory findings do not establish reliable anxiety relief in people.
Animal experiments suggest effects on signaling associated with GABA, a major calming chemical messenger in the brain. The exact human mechanism and clinical significance remain uncertain.
A change in rat brain gene expression does not prove reliable anxiety relief or cognitive enhancement in people. [30]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Semaglutide (GLP 1, R 1)
Semaglutide is a peptide medicine that imitates GLP-1, a natural hormone involved in appetite and blood sugar control. It helps strengthen meal-related signals that influence eating and the release of insulin. To picture its action, imagine a message from the digestive system to the brain and pancreas becoming easier to hear and lasting longer. Specific prescription formulations have been studied for defined medical uses.
It activates GLP-1 receptors, helping regulate food intake and stimulating insulin release when blood sugar is elevated. It also slows stomach emptying.
Approved medicines and large clinical trials support specific uses. Benefits and risks depend on the product and patient; a research vial is not automatically equivalent to an approved medicine. [31]
The official label identifies selective GLP-1 receptor activation, glucose-dependent insulin secretion and glucagon suppression, appetite effects and delayed gastric emptying. Separate changes in food intake, glycemic control and body weight when interpreting outcomes. Formulation-specific labeling governs approved uses. [31, 47]
Full compound profile →Semax
Semax is a synthetic peptide studied for its effects on nervous-system signaling. Researchers are interested in pathways involved in nerve-cell survival, adaptation and responses to injury. Think of the brain as a communication network that must maintain and adjust its connections: Semax research asks whether it changes some of the signals supporting that work. Changes in those signals are distinct from demonstrated improvements in memory or recovery.
Rat experiments have found changes in BDNF and its receptor. BDNF is a protein involved in the survival and adaptability of nerve cells.
Animal signaling changes do not establish better memory, stroke recovery or neuroprotection in every human setting. These claims require appropriate clinical evidence. [32]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Sermorelin
Sermorelin is a peptide that imitates the active part of the body’s growth-hormone-releasing signal. It prompts the pituitary gland to release growth hormone, provided that the gland can respond. A simple analogy is ringing a factory’s doorbell to request production. The response depends on the factory’s working capacity, so the same signal does not necessarily produce the same result in every person.
It activates receptors on the pituitary that encourage growth hormone release. Its effect depends on the person’s own hormone system being able to respond.
Human studies demonstrate hormone release. That mechanism alone does not establish that it reverses aging or improves performance in healthy adults. [33]
The relevant research question is whether a functioning pituitary responds to GHRH receptor stimulation and whether hormone changes translate to a meaningful clinical outcome. Empower’s material is consistent with this dependence on endogenous pituitary function; its broader benefit descriptions are not treated as trial confirmation. [33, 44]
Full compound profile →SS-31 (MTP-131)
SS-31, also called elamipretide or MTP-131, is a small peptide that acts within mitochondria, the cell’s energy-producing structures. It interacts with a specialized fat in their inner membrane. Picture a power plant whose equipment depends on the organization of its internal workspace: this peptide is studied for helping support that organization and function. Its specific medical evidence should be distinguished from broader claims about energy or aging.
It binds cardiolipin, a specialized fat in the inner mitochondrial membrane. This interaction is intended to support membrane organization and mitochondrial function.
Forzinity received accelerated FDA approval in 2025 for improving muscle strength in Barth syndrome patients weighing at least 30 kg. This narrow indication does not establish general anti-aging benefits. [34, 35]
The current label describes localization to the inner mitochondrial membrane and binding to cardiolipin. Accelerated approval rests on knee extensor strength, an intermediate endpoint; confirmatory evidence remains important. This should not be presented as proof of general rejuvenation. [34, 35]
Full compound profile →TB-500
TB-500 is a name associated with research on thymosin beta-4, a peptide involved in cell movement and tissue biology. The name is used inconsistently: it may refer to a short fragment or to a product described as the full-length peptide. Think of the difference between one component of a repair kit and the complete kit. Identifying which molecule is present is necessary before explaining what the research means.
Thymosin beta-4 interacts with actin, a protein involved in cell shape and movement. Related experiments investigate cell migration and wound repair, but a fragment cannot automatically be assumed to behave like the whole peptide.
Confirm the sequence. The cited fragment and full-length studies do not establish routine human injury-healing benefits for any product called TB-500. [13, 36]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Tesamorelin
Tesamorelin is a peptide medicine that encourages the pituitary gland to release growth hormone. It is used for excess abdominal fat associated with a specific condition in adults with HIV. To picture its role, imagine sending a signal that changes how the body coordinates certain fat stores. That specific medical use does not make it a general treatment for ordinary belly fat or overall weight loss.
It stimulates the pituitary to release growth hormone, which increases downstream IGF-1 signaling and affects body composition.
Egrifta is indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not a general weight-loss medicine, and that indication should not be generalized to ordinary belly fat. [37]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Full compound profile →Thymosin Alpha 1 (TA-1)
Thymosin Alpha 1 is a peptide studied for its role in coordinating immune responses; its synthetic form is also called thymalfasin. The immune system contains many different cells that must communicate and respond appropriately to threats. A useful analogy is a coordinator helping several teams exchange messages. Better coordination is a research question tied to particular diseases and circumstances, rather than a universal increase in immunity.
Experimental studies show effects on immune-cell signaling and communication between early defenses and more targeted immune responses. Its actions depend on the biological situation.
Clinical research exists, but benefit is condition-specific. A large randomized sepsis trial did not show reduced 28-day mortality. “Immune regulation” does not mean a universal immune boost. [38, 39]
Identify the exact molecule, experimental model, route and measured outcome in the cited work. Receptor activity or a biomarker change is not itself evidence of clinical benefit. Adequate comparison groups and follow-up are needed to assess efficacy and safety.
Full compound profile →Tirzepatide (GLP 2, T 60)
Tirzepatide is a peptide medicine that acts on two hormone receptor systems, GIP and GLP-1, involved in the body’s response to food. These pathways influence insulin release, appetite and other metabolic functions. Imagine two related communication channels being engaged by one message. Specific prescription products have evidence for defined uses, while the outcomes depend on the formulation, condition and patient population.
These hormone pathways influence blood sugar control and food intake. Tirzepatide reduces appetite and slows stomach emptying, contributing to its effects on weight.
Approved products support specific uses, including diabetes and weight management. Their evidence does not automatically transfer to every compounded or research-labeled preparation. [40]
Compare randomized groups, treatment duration, discontinuations and adverse events alongside weight and metabolic outcomes. Results depend on the tested population and formulation. A trial of a combination cannot isolate the contribution of one ingredient without suitable comparison groups.
Full compound profile →Wolverine (BPC-157\TB-500)
WOLVERINE is a blend name used for BPC-157 and TB-500, ingredients associated with tissue-repair research. The idea is to combine compounds investigated for related aspects of cellular repair. Think of pairing two tools intended for connected jobs: the rationale for putting them together is separate from evidence that the pair improves healing. The exact TB-500 molecule and blend proportions are necessary to assess any research claim.
It combines ingredients studied in tissue-repair signaling. The blend’s nickname does not describe a proven healing effect, and the exact identity of the TB-500 ingredient still matters.
The ingredient research does not demonstrate that this exact mixture heals human injuries faster or is safer than its components alone. [3, 13, 36]
Record every component, sequence, ratio and formulation. A study of one ingredient does not establish efficacy, stability or interaction effects of the combination. A useful comparison would test the complete blend against its components and an appropriate control.
Full compound profile →HCG
HCG, or human chorionic gonadotropin, is a naturally occurring hormone involved in reproductive biology. It can act much like luteinizing hormone, helping signal testosterone production in the testes or supporting ovulation-related processes in the ovaries. Picture a substitute messenger that can deliver a familiar instruction to reproductive tissues. It is distinct from growth hormone and has specific hormonal and reproductive medical uses.
It acts much like luteinizing hormone, stimulating testosterone production in the testes or supporting ovulation-related functions in the ovaries.
Prescription products have specific reproductive and hormonal indications. HCG is not established as a weight-loss treatment and is not the same hormone as human growth hormone. [41]
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
Sources and further reading
Selected primary studies and official prescribing information reviewed for this guide. Study descriptions below are short reading labels, not verbatim publication titles. Supplier material is used only to clarify product naming; it does not establish medical benefit. This is a focused educational reference, not a systematic review. Directory provenance The original directory scope was assembled from two PeptideFacts.com directory screenshots and a supporting compound reference on November 4, 2026. These materials establish naming and coverage only; they do not establish clinical efficacy.
- AOD9604 and fat metabolism in mice
- BPC-157 and tendon fibroblast signaling
- BPC-157 in rat Achilles tendon injury
- Cagrilintide randomized phase 2 weight-management trial
- Long-acting CJC-1295 in healthy adults
- Ipamorelin discovery and receptor pharmacology
- DSIP placebo-controlled chronic insomnia study
- Epithalon and telomerase in cultured human cells
- GHK-Cu and collagen synthesis in fibroblast cultures
- GHRP-2 and food intake in healthy men
- GHRP-6 and endogenous GHRH in healthy men
- TB-500 fragment identification and experimental activity
- Oral glutathione randomized trial
- LR3IGF-I and binding proteins in animal experiments
- Kisspeptin-10 and reproductive hormone release in humans
- Kisspeptin-54 and egg maturation in IVF
- KPV in cell and mouse intestinal inflammation models
- LL-37 early randomized topical wound trial
- LL-37 multicenter randomized wound trial
- Melanotan II early human pilot study
- MOTS-c and metabolic regulation in experimental models
- MOTS-c and cellular metabolic-stress signaling
- NAD+ human infusion metabolism pilot study
- Pitocin oxytocin prescribing information
- Vyleesi bremelanotide prescribing information
- Retatrutide randomized phase 2 trial
- RT RO-R3 supplier listing used for naming only
- Selank and GABA-related gene expression in rats
- Wegovy semaglutide prescribing information
- Semax and BDNF signaling in rats
- GHRH 1–29 hormone-response study in men
- Forzinity elamipretide prescribing information
- FDA Forzinity accelerated approval announcement
- Full-length thymosin beta-4 experimental wound repair
- Egrifta WR tesamorelin prescribing information
- Thymosin alpha 1 and experimental immune signaling
- Thymosin alpha 1 randomized phase 3 sepsis trial
- Zepbound tirzepatide prescribing information
- Pregnyl HCG prescribing information
- Doctor Pharmacist dosage chart and linked compound profiles reviewed November 4, 2026
- DailyMed labeling database
- Empower sermorelin injection profile
- PeptideDosages directory and linked Adamax and BPC-157 profiles
- Human ipamorelin pharmacokinetic and pharmacodynamic study
- Wegovy prescribing information
- Ionescu M and Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91:4792–4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Scenesse afamelanotide implant prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48
- National Cancer Institute Drug Dictionary — afamelanotide and Melanotan I naming. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afamelanotide
Revised product and vial reference
These archived comparison notes accompany the November 6, 2026 reference. See the calculator for current source rows. Reported schedules describe the source for each preparation.
The revised table omits a target-amount column. Single-compound implied amounts use the labeled vial quantity × reported U-100 UNITS ÷ (100 × added mL). The BPC-157 20 mg / 3 mL and 5 mL entries retain their explicitly stated targets and show the difference from the latest reported UNITS. Blend amount bases remain unconfirmed. No mass-to-IU conversion is inferred.
Some retained notes discuss older variants absent from the revised table. They are preserved as source context and do not recreate removed calculator rows. The SS-31 washout sentence is incomplete; no missing duration is supplied.
Explore all revised quantities →PeptideFacts | Master Product & Vial Reference
ResearchOnly.com catalog cross-check
Public catalog: https://researchonly.com/ | COA index: https://researchonly.com/coa/ . COA-listed sizes are evidence of tested lots, not necessarily every currently purchasable option. Some listings use aliases (e.g., RT (RO-R3), MT-1, MTP-31 and T-60).
| Compound | Observed sizes | Evidence |
|---|---|---|
| BPC-157 / TB-500 (WOLVERINE) | 10 mg, 20 mg | COA index |
| GHK-Cu | 50 mg, 100 mg | COA index |
| MOTS-C | 10 mg, 40 mg | COA index |
| RT (RO-R3) | 10 mg, 20 mg, 30 mg, 50 mg | COA index |
| T-60 | 10 mg, 20 mg, 40 mg | COA index |
| MTP-31 | 10 mg, 50 mg | COA index |
| Tesamorelin | 10 mg, 20 mg | COA index |
| KPV | 10 mg | product specification |
| Semax | 30 mg | separate research-only.com site; NOT researchonly.com |
Important: research-only.com and researchonly.com are different web addresses. This draft uses researchonly.com as requested; the similarly named site is not used as the inventory authority.
GLP & metabolic profiles — view revised rows in the calculator →
Growth-hormone & related profiles — view revised rows in the calculator →
Tissue, immune & blend profiles — view revised rows in the calculator →
Other compounds & formulations — view revised rows in the calculator →
Neuroactive & mitochondrial profiles — view revised rows in the calculator →
Interpretation and source notes
* Amount means compound mass per reported administration unless explicitly stated per day, per component or in IU. A range preserves differing reports; neither endpoint is a recommendation. Numeric units match both endpoints in the same order. † More than 100 units exceeds a 1 mL syringe; no split-injection plan is implied. Decimal values may not be measurable on a particular syringe. BPC-157 20 mg rows: 0.5 mg is the target amount. Rounded U-100 values: 8 units at 3 mL corresponds to approximately 0.533 mg; 13 units at 5 mL corresponds to 0.52 mg. Exact equivalents for 0.5 mg are 7.5 and 12.5 units, respectively. GHRP-2 Anti-aging and Performance \ Athletic protocol labels and amounts are user-selected arithmetic entries, not clinically validated protocols or evidence of these benefits. The user-selected frequencies are not verified dosing recommendations. GHRP-2 0.15 mg target rows: rounded U-100 values of 5 units at 3 mL and 8 units at 5 mL correspond to approximately 0.1667 mg and 0.16 mg, respectively. Exact equivalents are 4.5 and 7.5 units. GHRP-6 Anti-aging and Performance \ Athletic labels, amounts, and frequencies (once daily for Anti-aging; twice daily for Performance \ Athletic) are user-selected arithmetic entries, not clinically validated protocols or evidence of these benefits. GHRP-6 0.15 mg target at 3 mL: exact U-100 equivalent is 4.5 units; the rounded 5-unit entry corresponds to approximately 0.1667 mg. Other GHRP-6 entries are exact arithmetic equivalents for their stated target amounts. GHRP-6 Performance \ Athletic rows show 0.2 mg per administration, twice daily: 6 U-100 units at 3 mL or 8 units at 4 mL. These are exact arithmetic equivalents. GHRP-2 Performance \ Athletic rows show a 0.15 mg target per administration, twice daily. Rounded values are 5 units at 3 mL and 8 units at 5 mL per administration; the rounding equivalents noted above apply. Ipamorelin labels, target amounts, frequency and bedtime/fasting wording are user-selected, not clinically validated protocols or timing recommendations. At 10 mg in 3 mL, the 0.2 mg target equals 6 U-100 units; the selected 5 units corresponds to approximately 0.1667 mg. The 0.3 mg target equals 9 units; the selected 8 units corresponds to approximately 0.2667 mg per administration. IGF-1 LR3 weeks 5–6 at 1 mg in 3 mL: the 0.075 mg target equals 22.5 U-100 units; the user-selected rounded-down value of 22 units corresponds to approximately 0.0733 mg per administration. CJC/IPA 20 mg at 3 mL: the exact U-100 equivalent for 0.5 mg total blend is 7.5 units; rounding up to 8 units gives approximately 0.5333 mg total blend.
[R] ResearchOnly.com product pages for Adamax, KPV and CJC/IPA were checked October 23, 2026. Labeled masses: 10 mg, 10 mg and 5 + 5 mg. Calculations use labels, not measured batch masses. Other original vial variants remain comparison entries rather than a complete current inventory audit.
[B] GLOW baseline uses a reported 2 mg GHK-Cu target: 2.8 mg total for a 50/10/10 mg blend. Additional source B2 instead reports 3.5 mg total, so both are documented rather than merged. B2 supplies a ratio-compatible KLOW figure of 4 mg total for 50/10/10/10 mg. Sources: https://helicalabs.com/peptides/glow ; https://helicalabs.com/peptides/klow ; https://bioamplified.com/dosage . Neither establishes safety or efficacy.
[T] TB-500 source reports maintenance 2–4 mg every 1–2 weeks; its separate loading report is 4–8 mg per WEEK divided into 2–3 administrations. A weekly total is not a per-administration amount. Source: https://helicalabs.com/peptides/tb-500
[G] Glutathione report is 600–1200 mg per IV session, not a subcutaneous serving size. [O] Oxytocin report is intranasal 10–40 IU; do not infer milligrams or syringe units without product-specific potency. Sources: https://helicalabs.com/peptides/glutathione and https://helicalabs.com/peptides/oxytocin
Source index
Accessed October 23, 2026. H sources are vendor-authored reports of anecdotal practice. Their statements about what is common have not been verified with a representative survey or 7-source agreement. This document does not adopt their clinical or regulatory claims. Original 2 and 3 mL rows are mathematical comparisons, not verified formulation recipes; the IGF acid rows and tesamorelin BAC-only rows remain unverified preparation assumptions.
[H1] https://helicalabs.com/peptides/aod-9604
[H2] https://helicalabs.com/peptides/cagrilintide
[H3] https://helicalabs.com/peptides/mots-c
[H4] https://helicalabs.com/peptides/retatrutide
https://helicalabs.com/peptides/semaglutide
https://helicalabs.com/peptides/tirzepatide
[H7] https://helicalabs.com/peptides/cjc-1295
[H8] https://helicalabs.com/peptides/ghrp-2
[H9] https://helicalabs.com/peptides/ghrp-6
[H10] https://helicalabs.com/peptides/igf-1-lr3
[H11] https://helicalabs.com/peptides/ipamorelin
[H12] https://helicalabs.com/peptides/kisspeptin-10
[H13] https://helicalabs.com/peptides/sermorelin
[H14] https://helicalabs.com/peptides/tesamorelin
[H15] https://helicalabs.com/peptides/hcg
[H16] https://helicalabs.com/peptides/bpc-157
[H17] https://helicalabs.com/peptides/ghk-cu
[H18] https://helicalabs.com/peptides/kpv
[H19] https://helicalabs.com/peptides/ll-37
[H20] https://helicalabs.com/peptides/thymosin-alpha-1
[H21] https://helicalabs.com/peptides/cjc-1295-ipamorelin
[H22] https://helicalabs.com/peptides/wolverine-bpc-157-tb-500
[H24] https://helicalabs.com/peptides/epitalon
[H25] https://helicalabs.com/peptides/mt-2
[H26] https://helicalabs.com/peptides/pt-141
[H27] https://helicalabs.com/peptides/dsip
[H28] https://helicalabs.com/peptides/nad-plus
[H29] https://helicalabs.com/peptides/ss-31
[N] Selank: intranasal 0.25–0.5 mg per administration. Semax: source reports intranasal daily totals from about 0.3 mg to several milligrams, without one per-administration amount. Sources: https://helicalabs.com/peptides/selank and https://helicalabs.com/peptides/semax
[A] NTN Performance authored schedule reports Adamax 0.3–1 mg daily. No validated dose is inferred. https://ntnperformance.com/protocols/adamax/
[R] https://researchonly.com/product/adamax/ ; https://researchonly.com/product/kpv/ ; https://researchonly.com/product/cjc-ipa/
Source-access limits: RetaGrade and NovoVita supplied arithmetic references rather than dose selection. CoreViles and Doctor Jay’s Peptides could not be reliably resolved from the supplied names; Amino Labs was ambiguous. could not be confirmed as the exact named source. No unavailable source is counted as agreeing. Additional source:https://texas-best-compounding.com/peptide-mixing-and-dosing-1/ reports BPC-157 0.3–0.6 mg with its own sodium-chloride formulation and DSIP 0.1–0.5 mg with its own premixed liquid; those formulations are not transferred to this catalog.
Expanded comparison of reported amounts
Additional sources checked October 23, 2026. The baseline is retained for comparison. Agreement means overlap between named reports, not a vote establishing a correct dose. Repeated text may share an upstream source. Different routes, loading and maintenance phases, and pharmaceutical formulations are not interchangeable.
| Compound | Additional reported amount | Assessment |
|---|---|---|
| AOD-9604 | B2: 0.3 mg | Matches amount; frequency differs. |
| BPC-157 | B2: 0.5 mg; P1: 0.3–0.6 mg | Overlaps baseline; P1 uses sodium chloride. |
| Cagrilintide | B2: 0.5 → 2.4 mg | Initiation versus later amount; retain distinction. |
| CJC No DAC | B2: 0.2 mg | Differs from baseline 0.1 mg. |
| CJC/IPA | B2: 0.25 + 0.25 mg | Differs from baseline 0.1 + 0.1 mg. |
| DSIP | B2: 0.25 mg; P1: 0.1–0.5 mg | Overlap; P1 premixed formulation differs. |
| Epithalon | B2: 2 mg | Below baseline 5–10 mg; disputed. |
| GHK-Cu | B2: 1.7 mg | Within baseline range. |
| GLOW | B2: 2.5 + 0.5 + 0.5 mg | 3.5 mg total; differs from baseline 2.8 mg. |
| HCG | B2: 250–500 IU | Amount overlaps; indication still matters. |
| IGF-1 LR3 | B2: 0.05 mg | Amount overlaps; schedule differs. |
| Ipamorelin | B2: 0.3 mg | Within baseline range. |
| Kisspeptin | B2: 0.125 mg | Above baseline 0.05–0.1 mg; form/route not established. |
| KLOW | B2: 2.5 + 0.5 + 0.5 + 0.5 mg | 4 mg total matches listed vial proportions; source-labeled entry added. |
| KPV | B2: 0.5 mg | At baseline upper bound. |
| LL-37 | B2: 0.125 mg | Within baseline range; no clinical validation implied. |
| MOTS-C | B2: 5–10 mg | Wider than baseline single figure. |
| NAD+ | B2: 100 mg | Within baseline range. |
| PT-141 | B2: 0.5 mg; L3: 1.75 mg | B2 below baseline; labeled drug is a distinct product. |
| SS-31 | B2: 0.5 mg; L4: 40 mg | Major disagreement; L4 specific to Barth syndrome. |
| TB-500 | B2: 0.5 mg daily | Different exposure pattern from baseline maintenance. |
| WOLVERINE | B2: 0.25 + 0.25 mg | Total at baseline lower bound; ratio must match. |
Not combined: B2 does not establish a comparable injected amount for oxytocin, Selank or Semax in the brief table. Those entries require route and formulation confirmation. No additional independent amount was established in this pass for GHRP-2, GHRP-6, thymosin alpha-1, Adamax, or glutathione. They retain their original source labels; evidence gaps remain visible.
Pharmacy comparisons and formulation corrections
[P2/P3/P4] Sermorelin: Empower’s compound page reports 0.2–0.3 mg daily, and Olympia reports 0.3 mg nightly. These overlap the baseline. A separate Empower overview reports 0.2–1 mg/day and describes 0.5 mg as common. This is disagreement within one publisher, not 2 independent confirmations; the baseline is not expanded into a recommendation.
[F1] Tesamorelin: EGRIFTA WR labeling specifies 1.28 mg daily and says WR and SV are not substitutable. Its 11.6 mg vial and specified diluent procedure differ from this draft’s 10/20 mg research-vial assumptions. The user-selected 1 mg and 2 mg amounts, BAC-only preparation, 5-day frequency, and washout schedule are not WR labeling instructions. WR label concentration must be taken from its labeling, not inferred by dividing nominal vial content by diluent volume.
[L1/L2] Semaglutide 0.25 mg weekly and tirzepatide 2.5 mg weekly are initiation amounts for the cited approved products, generally for the first 4 weeks. This corroborates the numbers’ origins, not research-vial equivalence or a continuing maintenance amount.
[L3] VYLEESI specifies 1.75 mg as needed for its approved indication, no more than 1 time per 24 hours; more than 8 doses monthly is not recommended. This does not validate vendor PT-141 vials or establish a universal range for men and women.
[L4] FORZINITY (elamipretide, also known as SS-31) received accelerated FDA approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Its labeled amount is 40 mg daily in that defined setting. Helica’s claim that SS-31 is unapproved is outdated. Neither that label nor the conflicting online amounts establishes a general longevity dose; the baseline 5–10 mg must remain source-reported only.
[T2/T3] Retatrutide: the 2023 phase 2 trial used 1, 4, 8 and 12 mg weekly groups, with starting amounts of 2 or 4 mg in escalating groups. A 2026 phase 3 report describes 4, 9 and 12 mg target groups. These trial arms do not confirm the whole baseline 0.5–2 mg community starting range and do not identify one universal serving.
Additional sources actually used
[B2] BioAmplified reported-amount table. Online educational/affiliate reference; broad comparison, not clinical validation. https://bioamplified.com/dosage
[P1] Texas Best Compounding. Pharmacy-authored formulation comparison for BPC-157 and DSIP. https://texas-best-compounding.com/peptide-mixing-and-dosing-1/
[P2] Empower sermorelin compound page. Pharmacy-authored amount reference. https://www.empowerpharmacy.com/compounding-pharmacy/sermorelin-acetate-injection/
[P3] Olympia sermorelin chart. Pharmacy-authored amount reference. https://www.olympiapharmacy.com/blog/sermorelin-dosage-chart/
[P4] Empower growth hormone overview. Same publisher as P2; conflicting broader range. https://www.empowerpharmacy.com/compound-medication/hormone-replacement/growth-hormone-therapy/
[F1] FDA EGRIFTA WR label. Product-specific dose, diluent and non-substitutability. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
[L1] Novo Nordisk OZEMPIC label. Approved injection product initiation amount. https://www.novo-pi.com/ozempic.pdf
[L2] Eli Lilly ZEPBOUND label. Approved product initiation amount. https://pi.lilly.com/us/zepbound-uspi.pdf
[L3] DailyMed VYLEESI label. Approved-product amount and frequency limits. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
[L4] FDA FORZINITY label and approval. Product-specific amount and indication; approval correction. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf
[L4a] FDA FORZINITY approval announcement. Approval status. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
[T2] Jastreboff et al. 2023 phase 2 retatrutide trial. Original clinical research; trial arms, not general guidance. https://pubmed.ncbi.nlm.nih.gov/37366315/
[T3] 2026 phase 3 retatrutide publication. Original clinical research; target groups only used here. https://www.nejm.org/doi/full/10.1056/NEJMoa2604169
[Q1] FDA compounded semaglutide dosing-error alert. Why units require product-specific concentration. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
Earlier source index remains part of this document: Helica compound pages, Research Only product pages, NTN Performance Adamax. Consulted for arithmetic only: https://www.retagrade.com/research/reconstitution-guide ; https://www.retagrade.com/faq ; https://novovita.health/reconstitution/. Not counted as amount evidence: unresolved CoreViles and Doctor Jay’s names; ambiguous Amino Labs; unconfirmed exact identity; Happy Hormones DSIP patient PDF returned 404. Search-result listings alone are not independent confirmations.
[Q1] U-100 is a volume scale. FDA has reported serious errors when compounded semaglutide concentrations and syringe-unit instructions were confused. A correctly computed number cannot validate the source amount, purity, formulation or intended use.